Ophthalmology Phase 3 Readout Calendar
Industry-sponsored ophthalmology trials with primary completion in the next 12 months or last 12 months.
Data last updated July 17, 2026 · source: ClinicalTrials.gov
All areas OncologyImmunologyMetabolicCNSCardiovascularInfectious DiseaseRespiratoryRare DiseaseOphthalmologyDermatologyMusculoskeletalRenalPain
16
Next 6 months
19
Next 12 months
6
Results posted
77
Phase 3 Ophthalmology
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 ophthalmology trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
What ophthalmology trials are reading out soon?
The "upcoming" section shows industry-sponsored Phase 3 ophthalmology trials with primary completion ahead, soonest first, each graded by how credible that date is.
Which ophthalmology trials have already read out?
The "recently read out" section shows Phase 3 ophthalmology trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.
How are these readout dates sourced?
Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.
Where can I see readouts for other therapeutic areas?
The full cross-area calendar is on the main readout calendar; this page is the Ophthalmology slice of it.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Ophthalmology landscape →
Recently read out & awaiting topline — Ophthalmology
· 7Phase 3 ophthalmology trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Alcon Research | Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction | Ocular Hypertension +1 | Completed | Q2 2026 2026-04-06 | Completed · awaiting
Updated 3mo ago
| NCT07082816 |
| AbbVie | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma | Open-Angle Glaucoma | Completed | Q1 2026 2026-02-04 | Completed · awaiting
Updated 5mo ago
| NCT05411198 |
| Apellis Pharmaceuticals, Inc. | Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe Asset: APL-2, Pegcetacoplan | Geographic Atrophy Secondary to Age-related Macular Degeneration | Completed | Q4 2025 2025-12-12 | Completed · awaiting
Updated 7mo ago
| NCT07214740 |
| Apellis Pharmaceuticals, Inc. | An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD Asset: PEGCETACOPLAN (APL-2) | Geographic Atrophy Secondary to Age-related Macular Degeneration | Completed | Q3 2025 2025-09-05 | Completed · awaiting
Updated 9mo ago
| NCT04770545 |
| Regeneron Pharmaceuticals | A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) Asset: Aflibercept 8 mg | Neovascular Age-Related Macular Degeneration +1 | Active Not Recruiting | Q3 2025 2025-08-26 | Completed · awaiting
Updated 9mo ago
| NCT06491914 |
| AbbVie | Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension Asset: Bimatoprost (SR) | Open-Angle Glaucoma +1 | Completed | Q3 2025 2025-08-08 | Completed · awaiting
Updated 11mo ago
| NCT03850782 |
| Senju Pharmaceutical Science & Tec… | Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease Asset: SJP-0132 | Dry Eye | Completed | Q3 2025 2025-07-28 | Completed · awaiting
Updated 8mo ago
| NCT06717152 |
Upcoming ophthalmology readouts — next 12 months
· 19Industry Phase 3 ophthalmology trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| AbbVie | Long-term Safety and Efficacy Extension Trial of Bimatoprost SR Asset: Bimatoprost SR | Open-Angle Glaucoma +1 | Completed | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 11mo ago
| NCT03891446 |
| EyePoint Pharmaceuticals, Inc. | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 Asset: EYP-1901 | Wet Age Related Macular Degeneration +1 | Active Not Recruiting | Q3 2026 2026-08 (est.) | Estimated · fresh
Updated 4mo ago
| NCT06668064 |
| Kodiak Sciences Inc | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK Asset: Tarcocimab tedromer | Wet Age-related Macular Degeneration | Active Not Recruiting | Q3 2026 2026-08 (est.) | Estimated · aging
Updated 9mo ago
| NCT06556368 |
| Rophibio, Inc. | A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration Asset: RBS-001 Solution for intravitreal injection | Neovascular Age-related Macular Degeneration (nAMD) | Not Yet Recruiting | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 15mo ago
| NCT06470373 |
| Salutaris Medical Devices, Inc. | Adjunct Episcleral Brachytherapy for PCV Asset: Aflibercept Injection | Age-Related Macular Degeneration +1 | Not Yet Recruiting | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 35mo ago
| NCT05251636 |
Unlock 14 more ophthalmology readouts · plus filters on the full calendar
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.